Venetoclax induces profound and sustained responses in patients with relapsed/refractory light‐chain amyloidosis.

Keywords: AL amyloidosis; cardiac amyloidosis; venetoclax; BH3 mimetics; apoptosis EN AL amyloidosis cardiac amyloidosis venetoclax BH3 mimetics apoptosis 674 677 4 05/03/21 20210501 NES 210501 Systemic light-chain (AL) amyloidosis has a poor prognosis, especially when progressive heart failure occurs. Venetoclax induces profound and sustained responses in patients with relapsed/refractory light-chain amyloidosis We report here the results of a single-centre retrospective study on consecutive R/R AL amyloidosis patients treated off-label with venetoclax in a French academic referral centre between February 2017 and January 2020. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. [Extracted from the article]